DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181663

Impact of drug susceptibility on treatment outcome in sputum smear positive pulmonary tuberculosis patients receiving category-II regimen in RNTCP under field conditions in an urban setting

Ramesh P. M., Saravanan M.

Abstract


Background: The study was conducted with the aim to evaluate the pre-treatment drug susceptibility profile and to assess the influence of drug resistance on treatment outcome among patients treated with category- II (cat- II) regimen under programme conditions.

Methods: This study was conducted on 58 smear positive patients with history of previous anti-tuberculosis treatment for more than one month, comprising cases of ‘Failure’, ‘Treatment after Default’ (TAD) and ‘Relapse’. They received cat- II regimen in Chennai Corporation, RNTCP (revised National tuberculosis control programme) centers from July 2006 to September 2006 and they were monitored upto July 2007 as per RNTCP guidelines to assess the outcome of cat-II treatment by sputum smear status.

Results: Male dominance (n=40) was seen in the study participants. Most common age group affected was 35-44 years (n=20). Out of 57 cases, 50.9% cases come under ‘Relapse’, 26.3% arises from ‘TAD’ and 22.8% cases were from ‘Failure’. After completion of treatment with cat-II regimen, out of 57 patients 33 patients were cured and 11 cases were into the category of failure, 10 patients were defaulted during treatment and 3 were died.

Conclusions: Besides, the low treatment efficiency in MDR-TB cases, cat- II regimen was effective in sensitive and INH resistant cases.


Keywords


Category- II regimen, Drug susceptibility, RNTCP

Full Text:

PDF

References


TB′s History. Available from: http://www.library.thinkquest.org/C0126375/tb_in_the_world.htm. Accessed on 26 December 2012.

Han T. Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. Int J Evid Based Healthc. 2006;4:101-17.

Trivedi SS, Desai SE. Primary anti TB resistance and acquired Rifampicin resistance in Gujarat. India Tubercle. 1988;69:37.

Kuadan C, Bercion R, Jifon G, Cunin P, Blackett KN. Acquired anti-TB drugs resistance in Yaounde, Cameroon. Int J Tuberc Lung Dis. 2000;4:427.

Verma R, Khanna P, Mehta B. Revised national tuberculosis control program in India: The need to strengthen. Int J Prev Med. 2013;4:1-5.

Khatri GR. The revised national tuberculosis control programme: A status report on first 1,00,000 patients. Indian J Tuberc. 1999;46:157-66.

About RNTCP. Available at: http://www.tbcindia.nic.in/RNTCP.html. Accessed on 26 December 2012.

Khatri GR, Frieden TR. Controlling tuberculosis in India. New Eng J Med. 2002;347:1420-6.

TB India. RNTCP Status report. Central TB Division, Directorate General of Health Services. Ministry of Health and FamilyWelfare, Nirman Bhavan, New Delhi, 2004.

Ziehl–Neelsen technique. Available at: Online Microbiology Notes". Online Microbiology Notes. Accessed on 29 November 2017.

Revised National Tuberculosis Control Programme Technical guidelines for TB control. Central TB Division,Directorate General of Health Services,Nirman Bhavan, New Delhi, India, 1997.

Joseph P, Chandrasekaran V, Thomas A, Gopi PG, Rajeswari R, Balasubramanian R, et al. Influence of drug susceptibility on treatment outcome and susceptibility profile of ‘failures’ to category ii regimen. Indian J Tuberculosis. 2006;53:141-8

Vijay S, Balasangameshwara VH, Jagannatha PS, Saroja VN, Shivashankar B, Jagota P. Re-Treatment outcome of smear positive tuberculosis cases under dots in Bangalore City. Indian J Tuberculosis. 2002;49:199-204.

Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5:887.

Salaniponi FM, Nyirenda TE, Kemp JR, Squire SB, Godfrey-Faussett P, Harries AD. Characteristics, management and outcome of patients with recurrent tuberculosis under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 2003;7:948-52.